Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Orchestra BioMed targets BACKBEAT trial enrollment completion by Q3 2026, plans data presentation in Q2 2027.
MDT
$80.48
+$0.01 +0.01%

Orchestra BioMed targets BACKBEAT trial enrollment completion by Q3 2026, plans data presentation in Q2 2027.

Company Fundamentals
12 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Orchestra BioMed announced progress in its pivotal BACKBEAT Trial for AVIM Therapy, aiming to complete patient enrollment by the end of Q3 2026. The company, in collaboration with Medtronic, plans to present primary endpoint data at a major cardiology conference in Q2 2027, assuming trial success, followed by regulatory submissions. AVIM Therapy received a second FDA Breakthrough Device Designation for treating uncontrolled hypertension, potentially benefiting over 7.7 million U.S. patients. Orchestra BioMed also reported strong financial backing, including $35 million in recent strategic capital, supporting ongoing clinical trials and development milestones through Q4 2027.

More News (MDT)

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...

Market News
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App